Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
EUDA Health Holdings Limited
EUDA
NASDAQ·Healthcare·Medical - Healthcare Information Services·Mkt cap $28.0M
$13.88
▼ -0.86%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$5.26 - $86.00
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 80.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Early-mover advantage in Asian telehealth market
- Proprietary digital health platform technology
- Strategic subsidiary backing from Watermark Developments
- Streamlined non-emergency medical consultation process
Bear Case
1 risk
- Low volatility (beta 0.6).
Growth
Turning profitable
Increasing adoption of telehealth services post-pandemic
Value
Deep value opportunity - significant discount to Healthcare IT & Services peers
Momentum
Hot
+47.7% over 3m
Quality
Stable
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying EUDA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Jul 28, 2026
APR 28, 2026
Reported EPS of $0.40 vs $0.40 consensus (0.0% surprise). Revenue of $6.2M vs $6.4M expected (-3.0%).
EPS surprise · last 4Q
1 of 1 beats
Q2 26
0.0%
Next: Jul 28, 2026
Revenue trend · last 8Q
—
—
—
-14%
-5%
+10%
+60%
+60%
Q2 23
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
$1.1M
$951.7K
$954.0K
$954.0K
$1.1M
$1.1M
$1.5M
$1.5M
Margins · last 8Q
Gross
27.3%
Operating
-37.0%
Profit
-39.4%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Greenridge Global · Mar 9, 2026